Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
About this item
Full title
Author / Creator
Publisher
MDPI
Journal title
Language
English
Formats
Publication information
Publisher
MDPI
Subjects
More information
Scope and Contents
Contents
Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is required to optimize therapy decisions. Syndecan-1 (SDC...
Alternative Titles
Full title
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_71490fd378244d5eb3504b56efadd800
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_71490fd378244d5eb3504b56efadd800
Other Identifiers
ISSN
2075-4418
E-ISSN
2075-4418
DOI
10.3390/diagnostics10110864
